Evogene Confirms Board Slate at September 4 Shareholder Meeting
TipRanks (Fri, 4-Sep 10:59 AM ET)
PRNewswire (Mon, 31-Aug 8:00 AM ET)
PRNewswire (Tue, 25-Aug 7:01 AM ET)
Evogene Reports Second Quarter and First Half 2026 Financial Results
PRNewswire (Tue, 18-Aug 8:05 AM ET)
PRNewswire (Fri, 14-Aug 7:01 AM ET)
Evogene Schedules Second Quarter 2026 Financial Results Release
PRNewswire (Thu, 30-Jul 7:00 AM ET)
PRNewswire (Wed, 22-Jul 8:00 AM ET)
PRNewswire (Wed, 15-Jul 7:30 AM ET)
Market Chameleon (Thu, 9-Jul 6:30 AM ET)
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
Evogene Ltd. - trades on the NASDAQ stock market under the symbol EVGN.
As of September 8, 2026, EVGN stock price declined to $0.51 with 156,481 million shares trading.
EVGN has a beta of 1.22, meaning it tends to be more sensitive to market movements. EVGN has a correlation of 0.05 to the broad based SPY ETF.
EVGN has a market cap of $6.14 million. This is considered a Sub-Micro Cap stock.
Last quarter Evogene Ltd. - reported $347,000 in Revenue and -$.13 earnings per share. This beat revenue expectation by $22,000 and exceeded earnings estimates by $.14.
In the last 3 years, EVGN traded as high as $10.40 and as low as $.37.
EVGN has underperformed the market in the last year with a price return of -57.7% while the SPY ETF gained +19.2%. EVGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.7% and -9.8%, respectively, while the SPY returned +1.4% and 0.0%, respectively.
EVGN support price is $.50 and resistance is $.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVGN shares will trade within this expected range on the day.
